May 26, 2020
Impact of Baseline Dyskinesia on Safety and Efficacy of NOURIANZ® (istradefylline) in Patients with Parkinson's Disease Presented During "Virtual" European Academy of Neurology Meeting
Apr 27, 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
Mar 19, 2020
FDA Approves New Treatment for Pediatric Patients with Any Strain of Hepatitis C
Mar 18, 2020
Pharmascience Inc. launches pms-FLUTICASONE PROPIONATE/SALMETEROL DPI for the maintenance treatment of asthma and COPD
Mar 16, 2020
Vasomotor Symptoms Market Size is Growing at a CAGR of 7% | Some of the Major Players are KaNDy Therapeutics, Fervent Pharmaceuticals, Astellas Pharma, Sojournix, Mitsubishi Tanabe Pharma
Mar 06, 2020
European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
Mar 04, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
Mar 02, 2020
Eyevance Pharmaceuticals launches TOBRADEX® ST in the United States
Mar 02, 2020
Eyevance Pharmaceuticals launches TOBRADEX® ST in the United States
Jan 31, 2020
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
Jan 28, 2020
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
Jan 25, 2020
Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)
Jan 06, 2020
Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency
Nov 28, 2019
Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China
Nov 19, 2019
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
Nov 17, 2019
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Nov 04, 2019
Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Oct 16, 2019
Eyevance Pharmaceuticals Acquires TOBRADEX® ST and NATACYN®
Oct 07, 2019
Desperate For A Do-Over? New "Take Two" Campaign By Excedrin® Offers Migraine Sufferers A Second Chance To Re-Live Milestone Moments Marred By Migraines
Sep 26, 2019
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes